Viatris (VTRS)

Viatris, which has the symbol VTRS-Q, is perceived as a company that is being closely managed, primarily focusing on shareholder value despite its low growth metrics. One expert highlights its trading valuation at a low price-to-earnings ratio of 7-8x, indicating potential appeal for value investors. The company's origins as a spin-off from Pfizer are noted, but another expert suggests it has a limited market presence, categorizing it as a small-cap firm. Overall, the experts advocate for scrutinizing investment opportunities within the healthcare sector, particularly those that are perceived to be undervalued. The sentiment is cautiously optimistic, emphasizing the necessity for improved operational focus to enhance shareholder value.